iShares Biotechnology ETF
IBB
$210.82
Loading chart…
News
Latest headlines for this stock
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The article provides an in-depth analysis of the iShares Biotechnology ETF (IBB), a smart beta ETF with over $10.5 billion in assets that tracks the Nasdaq Biotechnology Index. With a 0.44% expense ratio and 252 holdings, IBB offers diversified exposure to biotechnology and pharmaceutical companies, though it carries higher risk with a beta of 0.70 and 20.59% standard deviation. The ETF returned 23.89% year-to-date and 51.48% over the past year as of August 2026, with top holdings including Amgen, Vertex Pharmaceuticals, and Gilead Sciences.